Bristol-Myers Squibb is expected to post Q1 2026 revenue of $10.92 billion and earnings of $1.44 per share, with the current stock price of $58.71 trailing the $63.21 average analyst target.
The primary focus for investors remains the momentum of the company's New Product Portfolio as it works to counteract the revenue impact of impending patent expirations for key blockbusters.
While flagship drugs like Eliquis are still showing mid-single-digit growth, the acceleration of newer launches like Reblozyl and Camzyos is vital for offsetting steep declines in legacy Revlimid sales. Analysts are also watching for confirmation of the company's improved full-year 2026 guidance, which recently projected revenue and profit levels that topped initial Wall Street models.